M14 InnoTek
- 0.510
- 0.0000.00%
InnoTek News
InnoTek Limited Announces Board Changes
Here's Why Shareholders Should Examine InnoTek Limited's (SGX:M14) CEO Compensation Package More Closely
Huaan Securities released a research report on April 17 stating that it gave Innote (688253.SH) a buy rating. The main reasons for the rating include: 1) extremely high revenue and profit growth, with core revenue +205% in 23; 2) profit release due to COV
Huaan Securities released a research report on April 17 stating that it gave Innote (688253.SH) a buy rating. The main reasons for the rating include: 1) extremely high revenue and profit growth, with core revenue +205% in 23; 2) profit release due to COVID-19 clearance, 1Q24 net profit +171%; 3) clinical guidelines urge accurate screening of respiratory pathogens and proper medication use. (Mainichi Keizai Shimbun)
SDIC Securities released a research report on April 16 stating that it gave Innote (688253.SH) a purchase rating, and the target price was 42.13 yuan. The main reasons for the rating include: 1) Incident: Innote released its 2023 annual report for the fir
SDIC Securities released a research report on April 16 stating that it gave Innote (688253.SH) a purchase rating, and the target price was 42.13 yuan. The main reasons for the rating include: 1) Incident: Innote released its 2023 annual report and quarterly report for the first quarter of 2024, and the performance is in line with expectations; 2) actively lays out overseas business to build a second development engine; 3) demand+policy aspects drive the boom in the respiratory pathogen testing industry; 4) the risk that assumptions and predictions fall short of expectations, the risk that the market's demand for respiratory pathogen detection products falls short of expectations, and the risk of industry competition progressing
Non-COVID-19 business boosts Innotek's performance in 2023 to maintain growth and significantly increase dividends
① In 2023, the non-COVID-19 business achieved revenue of 420 million yuan, an increase of 208.23% over the previous year, accounting for 87.82% of the overall revenue. ② “The company has registered products in Southeast Asia, but products in Europe and the US have not been released yet.”
Innote (688253.SH): Net profit in 2023 increased 15.44% year-on-year, and plans to distribute 4 yuan for 10 shares
On April 15, GLONGHUI (688253.SH) released its 2023 annual report. Operating revenue was 478 million yuan, up 7.03% year on year, net profit of 170 million yuan, up 15.44% year on year, after deducting non-net profit of 147 million yuan, up 10.99% year on year, with basic earnings of 1.28 yuan per share. The company plans to distribute a cash dividend of 4 yuan for every 10 shares to all shareholders.
Express News | Innote: Net profit of 146 million yuan in the first quarter of 2024 increased 171.44% year-on-year
InnoTek's (SGX:M14) Earnings Trajectory Could Turn Positive as the Stock Rallies 18% This Past Week
Dragon Tiger List丨Innocent dropped more than 15%, and the net sales of the five institutions were 136 million yuan
Glonghui, April 12 | Innote (688253.SH) plummeted 15.29% today, with a turnover of 466 million yuan and a turnover of 21.89%. According to data from the Dragon Tiger List, one agency bought 16.9614 million yuan, and the four institutions sold 154 million yuan. The total net sales of the institution was 136 million yuan.
Innotek Proposes First and Final Dividend
Innotek (SGX:M14) will propose a first and final dividend of SG$0.02 at the company's annual general meeting on April 26, a company filing with the Singapore Exchange disclosed on Thursday. The divide
Sudden! Leading shareholders of 36 billion Flying Motors plan to reduce their holdings by no more than 0.42% | Highlights of post-market announcements
Runhe Software: The holding subsidiary plans to increase capital and expand shares and introduce the Southern Network Institute of Mathematical Research
Innote (688253.SH) announced a pre-increase in net profit of 138 million yuan to 154 million yuan for the first quarter, surging 156.42% to 186.15%
Innote (688253.SH) disclosed its earnings forecast for the first quarter of 2024. The company expects to achieve business in the first quarter...
Express News | Innote: Net profit for the first quarter is expected to increase by 156.42% year-on-year to 186.15%
InnoTek Limited Announces New Company Secretaries
Innote (688253.SH): Key marketing products this year are still chromatographic products, and Jiulian products are dominated by steady growth
Gelonghui March 5 | Innote (688253.SH) disclosed an investor relations activity record table showing that this year's key marketing products are still chromatographic products, and Jiulian products are mainly growing steadily. Molecular products are expected to be launched soon. The products are positioned as routine testing items in hospitalization scenarios, and no separate equipment is required. As molecular platform technology matures, molecular POCT products are also the company's long-term plans.
Innote (688253.SH): At present, the product has basically achieved automated production capacity sufficient to meet sales needs
Gelonghui, March 5, 丨 Innote (688253.SH) disclosed an investor relations activity record sheet showing that at present, the company's products have basically been automated, and multiple automated production lines have been set up, and production capacity is sufficient to meet sales needs.
InnoTek Full Year 2023 Earnings: EPS: S$0.019 (Vs S$0.01 in FY 2022)
Some shareholders of Innote (688253.SH) reduced their holdings by a total of about 3.63%, and the reduction period of their holdings expired
Innote (688253.SH) issued an announcement. The company received a notification letter on March 1, 2024, as of 20...
Innote (688253.SH): Investment in the international market will be further increased in 2024
Glonghui, March 1 | Innote (688253.SH) recently said during a survey reception from institutional investors that in the international market, the company's goal is to use the international market as the second engine for the company's business development. In 2023, the company will use Thailand as a key market development in Southeast Asia. Judging from current progress, the market feedback on the specialized marketing strategy in the Thai market is very good. In 2024, the company will further increase its investment in the international market, strategically develop locally in the Southeast Asian market, and actively deploy in the European and American markets. Especially in the European market, standards for manufacturers after the new IVDR policy
Innote (688253.SH): Currently, the company has self-test products under development and is actively preparing for application
Glonghui, March 1 | Innote (688253.SH) recently said during a survey reception from institutional investors that in addition to COVID-19 products, the company currently has self-testing products under development and is actively preparing to apply. Judging from the international market, self-testing products are still very encouraged. In the future, if the company's self-test products are approved, the promotion of the company's self-test products will have a certain advantage, depending on the high market popularity established by the company's products such as the trifecta test kit for influenza A, B, and Mycoplasma pneumoniae antigen.
Analysis
Price Target
No Data
